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Abstract
Sickle cell disease (SCD) is a monogenetic disorder caused by a mutation in the [H9252]-globin 
gene HBB leading to polymerization of red blood cells causing damage to cell membranes, 
increasing its rigidity and intravascular hemolysis. Multiple lines of evidence suggest that SCD 
can be viewed as pan-vasculopathy associated with multiple mechanisms but driven by 
hemoglobin S polymerization. Here we review the pathophysiology, clinical manifestations and 
management strategies for cerebrovascular disease, pulmonary hypertension and renal disease 
associated with SCD. These “vascular phenotypes” reflect the systemic nature of the 
complications of SCD and are a major threat to the well-being of patients with the disorder.
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1. Introduction
Sickle cell disease (SCD) is a hematological hereditary condition characterized by 
structurally abnormal hemoglobin (HbS) that polymerizes to “sickle” red blood cells under 
unfavorable conditions such as hypoxia and stress. Historically, it has been traced back to a 
Ghanaian family who suffered from signs and symptoms suggestive of SCD in the year 1670 
[1]. It was, however, not until 1910 when Dr. James B. Herrick brought attention to a 
peculiar case of a dental student who had what is now known as SCD [2].
It is estimated that 5% of the world’s population carry genetic imprints responsible for 
hemoglobinopathies (primarily sickle cell and thalassemia) [3]. More specifically, 100,000 
Americans are thought to have SCD [4, 5] thus making it the most common 
hemoglobinopathy in the United States and likely worldwide. The “sickling” process does 
not have benign consequences and leads to various disease processes including vascular and 
non vascular complications. These can lead to significant impact on morbidity and mortality 
in patients with SCD. In fact, the median survival of adults with SCD was 42 in men and 48 
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in women in the 1990s [6]. There has been some interval improvement in survival with more 
recent data suggesting that the median survival has increased to 6th or 7th decade in life but 
continues to be consistently lower than contemporary adults without SCD [7–9].
SCD is due to a point mutation (substitution from glutamic acid to valine) in the beta-globin 
chain exclusively found on hemoglobin. In homozygous state, this leads to polymerization 
of hemoglobin causing damage to red blood cell membranes and increasing its rigidity [10–
12]. This rigidity can have two distinct effects as these deformed erythrocytes circulate 
throughout the body and can offer explanation to the spectrum of sickle cell complications. 
One effect is an increase in gelation and an obstructive adhesion of sickled cells which leads 
to hypoxic-ischemic-reperfusion injury to various organs. Phenotypically, it conforms to 
patients who suffer from vaso-occlusive pain crisis, acute chest syndrome and osteonecrosis. 
The other spectrum is recurrent hemolysis which leads to endothelial dysfunction and 
proliferative vasculopathy. This sub phenotype appears to be more common in patients with 
pulmonary hypertension, priapism, leg ulceration and stroke [13–16]. The latter is likely the 
main driver of vascular complications seen in SCD although both processes are not mutually 
exclusive (Fig. 1). The focus of this review will encompass the vascular complications of 
SCD which include cardiopulmonary vasculopathy, cerebral vasculopathy, and renal 
vasculopathy.
2. Pathophysiology
The fundamental role of the endothelium in various physiologic processes cannot be 
understated. In SCD, the vascular endothelium is markedly disrupted and dysregulated and 
is the converging cascade of the complex pathophysiologic processes linked to sickle cell 
vasculopathy [17]. Central to this endothelial dysfunction is the biodeficiency of nitric oxide 
(NO). NO is an endogenous vasodilator synthesized by endothelial cells by converting L-
arginine to citrulline and nitric oxide by endothelial NO synthase (eNOS). It is responsible 
for one-fourth of the resting blood flow and inhibition of which leads to increase in systemic 
blood pressure and decrease in regional blood flow [18–20]. NO does so by regulating basal 
vascular tone and inhibiting transcriptional factors implicated in endothelial adhesion and 
homeostatic activation [21–24]. The half-life of NO in the vasculature is very short because 
of rapid reaction with red blood cell hemoglobin to form methemoglobin and nitrate [25]. 
Yet, it is able to exert its vasodilatory effects on vascular smooth muscle because of the 
compartmentalization of hemoglobin within the erythrocytes. This compartmentalization 
minimizes scavenging of NO by intracellular hemoglobin [26]. However, intravascular 
hemolysis and resultant release of free hemoglobin potentiates the scavenging of NO leading 
to regional biodeficiency of NO. This reaction is so fast and irreversible that cell-free plasma 
hemoglobin levels of only 6–10 microM are sufficient to inhibit all NO signaling and 
produce vasoconstriction [27]. The release of heme from the hemoglobin molecule in 
plasma leads to activation of TLR4 and inflammasome pathways [28]. Additionally, 
hemolysis releases erythrocyte arginase-1 which metabolizes arginine into ornithine thus 
reducing the substrate needed for NO synthesis and decreasing its overall bioavailability. 
The redirection of arginine to ornithine by arginase-1 has downstream effects in the 
formation of polyamines and proline, which are involved in collagen synthesis and linked to 
proliferative vasculopathy of pulmonary hypertension and cardiovascular disease [29–32]. 
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The free hemoglobin also increases vasoconstrictor tone and amplifies NO resistance by 
inhibiting NO-dependent vasodilators [33]. Other contributors of increased NO resistance 
include NO synthase inhibitor such as asymmetric dimethylarginine. Interestingly, plasma 
levels of asymmetric dimethylarginine are 3-fold high in patients with SCD compared to 
healthy controls [34]. In fact, elevated levels of asymmetric dimethylarginine have also been 
linked to increased hemolysis, pulmonary hypertension and death [35]. Patients with SCD 
also have lower levels of apolipoprotein A-I which has been associated with abnormal 
endothelial function [36].
One other piece of this complex pathophysiologic picture is the role of reactive oxygen 
species (ROS) in generating NO resistance. Xanthine oxidase, NADPH oxidase and 
uncoupled endothelial NO synthase (eNOS) have been postulated to be sources of 
superoxide and hydrogen peroxide in SCD [37–39]. In particular, eNOS becomes 
dysfunctional “or uncoupled” in the setting of low levels of L-arginine or co-factor 
tetrahydrobiopterin (BH4) and starts production of superoxide instead of NO [40]. The ROS 
in turn can react with NO to form oxygen radicals such as peroxynitrite (ONOO-) further 
depleting NO bioavailability [41]. The downstream effect of chronic NO depletion leads to 
vasoconstriction, increased adhesion and platelet activation. There is endothelial activation 
which results in up regulation of potent vasoconstrictors such as endothelin −1. Adhesion 
molecules such as VCAM −1 are up regulated, platelet expression of intracellular arginase is 
increased and procoagulant factors are increased, all of which correlate with the degree of 
intravascular hemolysis [42–45].
Based on these observations, SCD can be viewed as “pan-vasculopathy” associated with 
multiple mechanisms but driven by hemoglobin S polymerization. The “vascular 
phenotypes” described in the next sections reflect the systemic nature of the complications 
of SCD.
3. Cerebral vasculopathy
There are many systemic consequences of SCD with cerebral vasculopathy such as stroke 
and chronic cerebral ischemia arguably being one of the most debilitating. Stroke was 
described in autopsy of children with SCD 13 years after Dr. Herrick’s original description 
[46]. Despite the numerous advances made in treatment, SCD remains one of the most 
common causes of stroke in children. The risk is highest in the first decade though, due to 
the protective effects of fetal hemoglobin, it is quite uncommon in the first two years of life. 
Strokes are clinically evident in 11% of patients with SCD before the age of 20 and up to 
24% by the age of 45. The occurrences of various stroke phenotypes differ with age with the 
ischemic subtype being more common up to the age of 20. However, during the third 
decade, for unclear reasons, the hemorrhagic variant becomes the dominant subtype [47]. 
Additionally, 10% to 30% of SCD patients may have silent strokes that exhibit radiologic 
findings consistent with diffuse white matter disease [48, 49]. Other manifestations include 
Moyamoya (Japanese term for hazy puff of smoke) which is defined as a chronic, occlusive 
cerebrovascular disease involving bilateral stenosis or occlusion of the terminal portion of 
the internal carotid arteries and/or the proximal portions of the anterior cerebral arteries and 
middle cerebral arteries [50]. The smoky angiographic appearance is the origin of its name 
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[51]. It has been associated with increased risk of recurrence of cerebrovascular events 
(CVAs) and thus suggests a poor prognosis [52].
The risks associated with stroke also vary with each subtype in SCD. Risk factors for silent 
strokes include lower hemoglobin levels, higher baseline systolic blood pressure and male 
sex [53]. Clinically evident ischemic strokes are associated with prior transient ischemic 
attacks, acute chest syndrome, and nocturnal hypoxemia [54]. Hemorrhagic variants have 
been linked to lower steady state hemoglobin and higher steady state leukocyte counts. 
Clinical features of CVA in SCD do not vary as compared to non-SCD control except that it 
is to be suspected in a younger cohort. However, in the event of silent infarcts, the most 
common presentation can be subtle cognitive deficits [55]. Therefore, high index of 
suspicion should be maintained at all times when evaluating patients with SCD especially in 
the pediatric age group. Unfortunately, often the clinical presentation represents the end 
point of a complex process that leads to devastating consequences.
A conscious effort was made to develop screening parameters to prevent cerebrovascular 
complications in children with SCD. In the 1990s, transcranial doppler (TCD) was explored 
as a potential imaging modality that could be used for the purposes of screening [56]. 
Subsequent work from the same group showed that children with “abnormal” TCD 
velocities, defined as greater than 200 cm/s in the large cerebral vessels, had an associated 
40% stroke risk within 3 years [57]. Furthermore, certain predisposing conditions can 
impact the development of abnormal TCD values in kids with SCD. The absence of alpha 
thalassemia, presence of G6PD (Glucose-6 phosphate dehydrogenase) deficiency, lower 
hemoglobin and increased LDH levels are associated with aberrant TCD values [58]. The 
use of TCD has been proven to have excellent sensitivity but lacks sufficient specificity 
which compromises positive predictive value [59]. However, a landmark study, the Stroke 
Prevention Trial in Sickle Cell Anemia (STOP I) successfully incorporated an “abnormal” 
TCD value as a criteria to transfuse children 2 to 16 years of age with SCD or sickle cell 
thalassemia with no prior history of stroke to maintain hemoglobin S (HbS) <30% and 
showed an absolute risk reduction of stroke from 30% to 3% over 30 months [60]. However, 
replicating the same results in adults has been challenging due to the fact the adults with 
SCD have lower doppler velocities and therefore the criteria used in children may not be 
predictive of determining individuals who are at greatest risk of developing stroke [61]. 
Based on these convoluted intricacies, consensus guidelines recommend annual screening 
with TCDs in children from age 2 to 16 but do not recommend such measures in adults with 
SCD [62]. Also, it is recommended to institute chronic transfusion therapy in children with 
elevated TCD parameters.
Receiving regular transfusions is not a benign phenomenon and is associated with some 
adverse effects which include alloimmunization, high ferritin levels and transfusion 
hemosiderosis. This was evident in the STOP I cohort where sixteen percent of transfused 
patients had treatment discontinued because of alloimmunization and ferritin levels rose by 
1500% over 24 months in the transfusion group. This has led to exploration of non-
transfusion modalities. Hydroxyurea emerged as a potential therapeutic option based on its 
ability to decrease the incidence of acute chest syndrome and painful crises [63]. Initial 
studies showed encouraging results in a small Belgian cohort [64] and more recently the 
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TWiTCH (TCD With Transfusions Changing to Hydroxyurea) trial confirmed its non-
inferiority when compared to chronic blood transfusions [65]. Perhaps, its role will expand 
to an acceptable alternative particularly if patients develop adverse effects to chronic 
transfusion therapy or do not have access to blood transfusions.
Management of ischemic stroke in SCD is divided in acute and long term management. 
Diagnostic imaging studies seem to favor the use of MRI/MRV if it can be obtained within 
60 minutes of presentation and can be paired with sequences to detect cerebral hemorrhage 
[66]. Acute management is not much different than the standard care of patients with 
ischemic stroke with two additional specific goals, i.e. reducing sickle cell hemoglobin 
levels to <30% of the total hemoglobin and raising the total hemoglobin to a level of 10 
g/dL. Both goals are concurrently achieved with administration of blood transfusions, either 
simple or exchange transfusions. Thrombolysis in SCD remains controversial because of the 
inherent risk of hemorrhagic conversion and increased incidence of hemorrhagic CVA in 
SCD compared to general population.
Long term management is arguably more complex with a common theme of secondary 
prevention. Roughly two-thirds of sickle cell patients who suffer from a cerebrovascular 
event have recurrence of such events [67]. Studies incorporating chronic blood transfusions 
with a goal of keeping sickle cell hemoglobin to less than 30% have consistently shown a 
reduction in recurrent strokes to less than 15% [68, 69]. This has been further validated with 
patients with silent cerebral infarcts (SCI). In the SIT (Silent cerebral Infarct Transfusion) 
trial, children with SCIs assigned to transfusion arm had statistically significant reduction in 
development of clinically evident strokes or new or enlarged silent cerebral infarcts (6% vs 
14%) [70]. In fact, cessation of such transfusion yields adverse outcomes with high risk of 
recurrent cerebrovascular events [71, 72]. Unlike its emergence in primary prevention, 
results of hydroxyurea as an alternative have been discouraging with the Stroke with 
Transfusions Changing to Hydroxyurea (SWiTCH) trial reporting a negative outcome in the 
hydroxyurea group. The trial was stopped early with the reporting of 7 cerebrovascular 
events in the hydroxyurea group when compared to none in the group received blood 
transfusions [73]. Interestingly, bone marrow transplantation seems to retard the progression 
of cerebral vasculopathy with subsequent reduction in strokes [74–76]. However further 
studies are needed to further elucidate the beneficial effects of bone marrow transplant in 
this subpopulation.
4. Cardiopulmonary vasculopathy
As scientific advances are being made to improve the survival of the sickle cell population, 
newer challenges have emerged that were previously under-recognized. Perhaps and 
arguably, the most challenging of these complications is the development of pulmonary 
hypertension. Pulmonary hypertension is defined as mean pulmonary artery pressure ≥25 
mm Hg at rest as determined by right heart catheterization [77]. Clinically, pulmonary 
hypertension is divided into 5 categories (Table 1) but hemodynamically it can be divided 
into two subtypes. If the pulmonary capillary wedge pressure (PCWP) or left ventricular 
end-diastolic pressure (LVEDP) at right heart catheterization is ≤15 mm Hg, it is termed as 
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precapillary pulmonary hypertension and if the PCWP or LVEDP is >15mm Hg, it is terms 
as postcapillary pulmonary hypertension.
Recent studies have shown that a minimum prevalence of pulmonary hypertension in adults 
from sickle cell disease ranges from 6–11%. This may be an underestimation due to certain 
exclusion criteria in some of the studies. It has also been linked to increasing morbidity and 
mortality [78–80]. The mortality in patients with SCD and pulmonary hypertension ranged 
from 12.5% to 37.5% when compared to SCD patients without pulmonary hypertension 
where mortality ranged from 0.8% to 17% at varying intervals of follow up. In an earlier 
smaller study, of patients undergoing right heart catheterization, 11 of 20 (55.0%) patients 
with pulmonary hypertension died over up to 9 years of follow up compared with 3 of 14 
(21.4%) without pulmonary hypertension [81]. This clearly signifies the importance of 
prompt and appropriate diagnosis.
The development of pulmonary hypertension is SCD is multifactorial resulting from the 
influence of chronic hemolysis, as detailed earlier, increased risk of thromboembolism, 
hypoxia driven gene expression and/or left ventricular dysfunction. Interestingly, pulmonary 
hypertension in SCD can be precapillary, postcapillary or a combination of both in a single 
patient [82]. This has led to its reclassification as World Health Organization (WHO) PH 
group 5 [83, 84]. It has long been known that patients with SCD have an inherent risk of 
developing venous thromboembolism [85]. Hemolysis and chronic NO depletion have been 
linked to increased platelet activation and contributes to a hypercoagulable state. The 
development of acute pulmonary embolism can progress to complications such as chronic 
thromboembolic pulmonary hypertension (CTEPH). Previously considered very rare (0.1–
0.5%) [86], more recent studies have suggested it to be in the range of 0.4–8.8% [87]. 
Therefore, thromboembolism has to be considered a contributor to the development 
pulmonary hypertension in SCD. This was outlined in one study where scintigraphic 
evidence suggestive of CTEPH occurred in approximately 12% of SCD patients with 
pulmonary hypertension [88]. Autopsies series confirm these findings including the presence 
of micro thrombi and distal thrombi [89–91]. Additionally, postmortem diagnoses of 
pulmonary hypertension and its association with thromboembolism has been described in 
another autopsy series [92].
Hypoxia is a potent vasoconstrictor of the pulmonary vasculature [93] and influences various 
processes that can lead to the development of pulmonary hypertension [94]. In SCD due to 
chronic anemia, there is an upregulation of erythropoietin which, in turn, increases the levels 
of circulating hypoxia inducible factor (HIF)-1[H9251] [95]. HIF-1[H9251] activation has 
been linked to the development of various forms of pulmonary hypertension through 
changes in mitochondrial redox signaling, fission, and numbers, and contributes to the 
development of a proliferative, apoptosis-resistant phenotype in pulmonary vascular cells 
[96–98]. Altered gene expression in SCD has been described which leads to increased levels 
of HIF-1 and HIF-2 at normoxia [99]. Additionally, MAPK8, a gene involved in promoting 
apoptosis, which is normally downregulated in response to hypoxia, has decreased 
expression in normoxic condition in patients with SCD. This resistance to apoptosis coupled 
with abnormal proliferation of pulmonary vascular smooth muscle is distinguished feature of 
pulmonary arterial hypertension. [100].
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Roughly half of the patients with pulmonary hypertension in SCD have post capillary PH. 
High cardiac output resulting from chronic anemia is primarily driven by increase in stroke 
volume and less by increase in heart rate. This leads to significant dilation of the left 
ventricle [101]. The response to this dilation is the development of eccentric hypertrophy in 
which wall thickening is increased and myofibers are elongated [102]. Over time, with 
increase in hypertrophy and left ventricular mass, diastolic dysfunction ensues. In fact, 
studies using standard Doppler parameters have shown that diastolic dysfunction is even 
found in children with SCD [103, 104]. In adults, this diastolic dysfunction is known to be 
an independent risk factor for decreased exercise tolerance [105] and increased mortality 
with a risk ratio of 4.8 [106].
There are various non-invasive tools that can be used to screen SCD patients for 
development for pulmonary hypertension. Doppler echocardiography, and NT-pro BNP are 
the most commonly used indices to gauge to possibility of developing pulmonary 
hypertension. Yet, both are imperfect tests which may have acceptable sensitivities but lack 
overall accuracy. However, they provide context for further testing which, even though is 
invasive, is the gold standard for diagnosing pulmonary hypertension i.e. right heart 
catheterization. Doppler echocardiography identifies important cardiac structures and their 
respective abnormalities but also estimates pulmonary artery systolic pressures via tricuspid 
regurgitation velocity (TRV). Using the Bernoulli equation, the tricuspid regurgitation 
velocity (TRV) can estimate right ventricular and pulmonary artery systolic pressures (PASP 
≈ 4*TRV2) after adding an estimate of the central venous or right atrial pressure. There is a 
positive correlation of TRV and echocardiography-estimated systolic pulmonary artery 
pressure with systolic pulmonary pressure measured at right heart catheterization in patients 
with SCD [107]. Pulmonary hypertension is considered to be unlikely if the TRV is ≤2.8 
m/sec and there are no other echocardiographic changes suggestive of pulmonary 
hypertension such as enlargement of right-sided chambers and right ventricular systolic 
dysfunction. The diagnosis is considered to be possible if the TRV is 2.9–3.4 m/sec and to 
be likely if it is ≥3.4 m/sec [108]. This has been validated in various studies using the above 
criteria. In one study, a TRV of at least 2.5 m/second identified PH with a sensitivity and 
specificity of 78 and 19%, respectively. The sensitivity decreased but the specificity 
increased to 67 and 81%, respectively, when a TRV of at least 2.88 m/second was used 
instead [109]. Serum NT-pro BNP level has also been evaluated as a non-invasive test that 
can be used to detect PH. However, most studies validating its use have marked limitations 
as the reference standard for PH used in those studies have been elevated TRV as opposed to 
direct hemodynamic measurements [110, 111]. Nonetheless, it appears to have value as a 
screening tool because the use of right heart catheterization for primary screening may not 
be acceptable to many patients due to costs and invasiveness.
Interestingly, there is data supporting the correlation of elevated TRV with mortality in SCD. 
Gladwin and colleagues [105] showed that mortality risk among patients with a TRV of at 
least 2.5 m/second was 10 times greater than that observed among patients with a TRV less 
than 2.5 m/second. Further analysis demonstrated that the degree of TRV elevation 
correlated with mortality; among patients with a TRV of 2.5–2.9 m/second and patients with 
a TRV of at least 3.0 m/second, the risk ratio for mortality was 4.4 and 10.6, respectively 
[112]. Further studies have reported similar findings [103, 113]. Similarly, NT-pro BNP has 
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also shown to correlate with mortality in SCD [108]. This was evident in a study of 330 
adults recruited as part of the Cooperative Study of Sickle Cell Disease, in which an NT-pro-
BNP level of at least 160 pg/ml was associated with a relative risk of death of 6.24 compared 
with those with lower levels [114]. On the basis of these studies, consensus guidelines 
advocate for the use of non-invasive testing for risk stratification, particularly doppler 
echocardiography, every 1 to 3 years in patients with diagnosed pulmonary hypertension and 
SCD [115].
As hemolysis appears to play a central role in the development pulmonary hypertension, 
logically, interventions that can improve anemia can lead to a favorable response. 
Hydroxyurea is lucrative option due to its ability to decrease hemolysis. Furthermore, 
extrapolated data from the MSH trial seems to favor the use of hydroxyurea in this cohort. 
Moreover, case-series targeting decreasing hemolysis with hydroxyurea has shown to 
improve pulmonary artery systolic parameters in SCD [116]. Therefore, in SCD patients 
with pulmonary hypertension who have increased risk of mortality, consideration should be 
made to start treatment with hydroxyurea. For patients with SCD who either are not 
responsive to hydroxyurea or not suitable candidates for hydroxyurea, chronic transfusion 
therapy has been suggested but there is no direct evidence to support its use. Advocacy of its 
use is based on extrapolated data from the STOP-1 cohort. Use of targeted pulmonary 
vasodilator therapy remains controversial. This is based primarily on the negative outcome 
of the Walk-PHaSST trial [117] where patients in the treatment group with sildenafil 
resulted in an increase in serious adverse events, primarily hospitalization for pain. However, 
for select patients who have catheterization confirmed marked elevation of PVR (≥2 Wood 
units), normal PAWP (≤15 mm Hg), and related symptoms, trial of either a prostacyclin 
agonist or an endothelin receptor antagonist can be considered [113].
Table 2 summarizes our suggested approach to the evaluation and management of patients 
with sickle and pulmonary hypertension.
5. Renal vasculopathy
The kidneys are the recipients of the entire cardiac output and therefore present as targets for 
vascular complications of SCD (Fig. 2). Thus renal dysfunction is one of the most common 
presentations of sickle cell vasculopathy. It is estimated that renal dysfunction in SCD 
ranges from 5 to 18% of the total population of SCD patients [118]. The median age of 
developing kidney disease in SCD ranges from 23.1 years in one series [119] to 37 years in a 
more recent study [120]. Clinical manifestations can vary from mild to severe dysfunction 
and the severity has been linked to increased mortality [121]. In one study, 25% of the 
patients die within 12 months of starting dialysis [122]. Thus, it is of paramount importance 
to recognize the development of renal vasculopathy in SCD as appropriate management can 
prevent progression of kidney disease and impact survival.
Apart from the general aberrant vascular response to stress seen in various other organs and 
described above, the most characteristic finding suggestive of renal vasculopathy in SCD is 
alteration in renal hemodynamics. Hyperperfusion, which occurs systemically, also occurs 
regionally; blood flow is increased in the forearm, pedal cutaneous area, brain, and kidney 
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[123]. Yet, the hypoxic, acidotic, and hyperosmolar environment of the inner medulla 
promote sickling of red blood cells with resultant impairment in renal medullary blood flow 
thus leading to microcirculatory regional defects. The combination of the hyperperfused 
whole kidney and the microcirculatory regional defects in the renal medulla leads to a 
“perfusion paradox” in SCD. This combined medullary hypoperfusion with cortical 
hyperperfusion and cyclical vasoconstriction leads to various renal manifestations of SCD.
Increased blood flow in SCD naturally results in increased filtration across the glomerulus 
thus leading to increased GFR [124]. This hyperfiltration has been observed in infancy and 
has been linked to the development of increased renal growth [125]. The leading hypothesis 
revolves around increased delivery of salt and water to the proximal tubule via 
hyperfiltration, which increases tubular reabsorption of sodium and water to restore 
glomerulotubular balance. As this is a highly aerobic metabolic process, it potentially 
stimulates mitochondrial and adaptive cellular responses which can lead to proximal tubular 
hyperfunction and renal enlargement [126]. Additionally, adaptive cellular responses can 
lead to cytokine and growth factor elevations which have positive effect on renal growth 
[127]. However, these processes over time can lead to cortical and glomerular capillary 
proliferation, interstitial edema, glomerular basement membrane thickening, 
glomerulosclerosis and fibrosis similar to histology seen in focal segmental 
gloumerulosclerosis (FSGS) [128–132]. This is thought to be primarily driven difference in 
the rate of glomerular enlargement when compared to relatively slower podocyte 
hypertrophy thus leading to areas of the glomerular basement membrane without podocyte 
foot processes. These denuded areas adhere to the parietal epithelium, thereby predisposing 
to FSGS. Additionally, the influx of cytokines promoting renal inflammation can lead to 
podocyte injury [133].
Glomerular disease inherently manifests as proteinuria which has been described as an age 
dependent phenomenon in SCD. It is estimated that about 30% patients with SCD develop 
proteinuria [134]. The presence of proteinuria is also associated with progressive CKD 
[135]. This occurs by the process described above i.e. continuous hyperfiltration causing 
gradual glomerular injury, increased glomerular growth causing damage to the endothelium 
leading to loss of podocyte integrity, and endothelial dysfunction from recurrent hemolysis 
[136].
Concomitantly, but contrary to hyperperfusion is the medullary hypoperfusion which 
manifests with simultaneous but distinguished clinical features. The high oxygen demand in 
the renal medulla is related to solute resorption which can lead to relatively low regional 
oxygen tension. This promotes sickling and congestion in the vasa recta, and resultant 
ischemia, impair both solute reabsorption by the ascending limb of the long loops of Henle 
and the capacity of the vasa recta to serve as countercurrent exchangers [137, 138]. These 
impairments lead to a decrease in solute accrual and retention in the medullary interstitium, 
thereby reducing interstitial osmolality. Over time, this leads to medullary fibrosis and 
clinically exhibits as the inability of concentrate urine (or hyposthenuria). This impairment 
has been described in infancy [139] and can lead to polyuria and eventual dehydration thus 
increasing the risk of precipitating a sickle cell crisis. Congestion of medullary vessels can 
also cause rupture and extravasation of red blood cells into the tubular lumen thus 
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precipitating a very common clinical presentation in SCD i.e. hematuria. Sometimes 
necrosis of the renal papilla from severe ischemia in the vasa recta can also present as 
hematuria [140]. Lastly, an additional effect of medullary hypoperfusion is the distal 
nephron dysfunction leading to impaired urine acidification and potassium excretion.
Despite a wide array of renal manifestations, there are no specific treatments for each 
manifestation. Most of the management is based on general management of SCD patients 
e.g. prevention of vaso-occlusive crisis as well as management related to chronic kidney 
disease e.g. optimal blood pressure control and dietary modifications. One relatively specific 
treatment is the use of ACE inhibitors if proteinuria develops. In a short trial with ACE 
inhibitor therapy in small number of patients with mild sickle cell nephropathy, there was a 
reduction in proteinuria by 57%, but returned to high levels after treatment withdrawal 
[141]. Similar results were reproduced in smaller studies [142, 143]. The combined use of an 
ACE inhibitor with hydroxyurea has been suggested to prevent the progression of 
microalbuminuria to frank proteinuria [144]. However, this combination therapy should be 
tested prospectively in patients with sickle nephropathy. Renal transplantation is a viable 
option in SCD related ESRD. In fact, no difference in one-year cadaveric renal graft survival 
rates has been observed between patients with SCD and the general transplant population 
[145]. However, the three-year cadaveric graft survival rate was slightly lower in patients 
with sickle cell nephropathy (48% versus 60%; p = 0.055), and the adjusted three-year risk 
of graft loss was significantly greater (p = 0.003) thus signifying the importance of 
continued close follow up in this population.
6. Conclusion
Sickle cell disease therefore should not be only viewed by its hematological roots but rather 
should be understood as a systemic pathological process with global complications that are 
often life threatening. A major unifying feature of the disease, however, seems to arise from 
endothelial dysfunction and its downstream effects which have varied phenotypic 
presentations. Therefore, ongoing and future research should also focus on the endothelium 
so that targeted therapies can reduce the risk of vascular complications of sickle cell disease.
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Fig. 1. 
Model of overlapping subphenotypes of sickle cell disease. Published data suggest that 
patients with sickle cell disease with higher hemoglobin levels have a higher frequency of 
viscosity-vaso-occlusive complications closely related to polymerization of sickle 
hemoglobin, resulting in erythrocyte sickling and adhesion. Such complications include 
vaso-occlusive pain crisis, acute chest syndrome, and osteonecrosis. In contrast, a distinct set 
of hemolysis-endothelial dysfunction complications involving a proliferative vasculopathy 
and dysregulated vasomotor function, including leg ulcers, priapism, pulmonary 
hypertension, and possibly non-hemorrhagic stroke, is associated with low hemoglobin 
levels, and high levels of hemolytic markers such as reticulocyte counts, serum lactate 
dehydrogenase, plasma hemoglobin and arginase, producing a state of impaired nitric oxide 
bioavailability. The spectrum of prevalence and severity of each of these subphenotypes 
overlap with each other. 16Adapted from Kato et al. Blood Rev. 2007 January; 21(1): 37–47.
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Fig. 2. 
Salient pathogenic processes in the development of sickle cell nephropathy. Sickle cell 
nephropathy largely reflects an underlying functional vasculopathy. This vasculopathy leads 
to a perfusion paradox, wherein medullary hypoperfusion occurs in conjunction with kidney 
and/or cortical hyperperfusion. The renal vasculopathy also leads to aberrant renal vascular 
responses to stress that occur systemically or in distant organs and tissues. This response is 
characterized by enhanced renal vasoconstriction and resultant vasoocclusion. Recurrent 
cycles of ischemia and ischemia–reperfusion injury thus occur, thereby leading to 
subclinical and clinical acute kidney injury. These processes summate in the initiation and 
progression of sickle cell nephropathy. [131]Adapted from Nath et al. Nat Rev Nephrol. 
2015;11 : 161–171.
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Table 1
Updated classification of pulmonary hypertension
1. Pulmonary arterial hypertension
 1.1 Hdiopathic PAH
 1.2 Heritable PAH
  1.2.1 BMPR2
  1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
  1.2.3 Unknown
 1.3 Drug and toxin induced
 1.4 Associated with:
  1.4.1 Connective tissue disease
  1.4.2 HIV infection
  1.4.3 Portal hypertension
  1.4.4 Congenital heart diseases
  1.4.5 Schistosomiasis
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
1” Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
 2.1 Left ventricular systolic dysfunction
 2.2 Left ventricular diastolic dysfunction
 2.3 Valvular disease
 2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
 3.1 Chronic obstructive pulmonary disease
 3.2 Interstitial lung disease
 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
 3.4 Sleep-disordered breathing
 3.5 Alveolar hypoventilation disorders
 3.6 Chronic exposure to high altitude
 3.7 Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
 5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
 5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
[83]Adapted from Simmonneau JACC 2013;62(25 Suppl):D34–41.
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Table 2
Suggested approach to screening, diagnosis and management of pulmonary hypertension in SCD
1 Screening for pulmonary hypertension by echocardiography
• Perform echocardiography every 1 to 3 years OR
• Perform echocardiography based on one or more findings consistent with increased risk
- Dyspnea on exertion
- Limited exercise capability as determined by the 6-minute walk test (<350 m)
- History of thromboembolism
- Pulse oximetry <95% at rest
- Previous echocardiogram with TRV of >2.5 m/sec
- Physical exam finding of right sided heart failure; lower extremity edema, hepatomegaly or jugular venous 
distension
- Elevated serum N- Terminal proBNP concentration
- Elevated serum creatinine concentration (>1.0 mg/dL for severe sickling phenotype and >1.4 mg/dL for mild 
sickling phenotype)
- LDH >475 U/L or reticulocyte count >300,000
- Serum ferritin >1000 ng/ml
2 Actions to be taken based on the results of the echocardiography
• TRV <2.5 m/sec: Ensure that patient is being managed according to NHLBI guidelines
• TRV 2.5–2.9 m/sec; normal right ventricle by echocardiography, no findings suggestive of pulmonary hypertension: 
Ensure that patient is being managed according to NHLBI guidelines and repeat echocardiogram yearly
• TRV 2.5–2.9 m/sec; right ventricular hypertrophy by echocardiography and/or other findings consistent with increased 
pulmonary hypertension risk: Ensure that patient is being managed according to NHLBI guidelines; refer to 
pulmonary hypertension expert for right heart catheterization
• TRV >3 m/sec: Ensure that patient is being managed according to NHLBI guidelines and refer to pulmonary 
hypertension expert for right heart catheterization
3 Actions to be taken based on the results of the right heart catheterization
• mPAP <25 mm Hg: Pulmonary hypertension not present. Ensure that patient is being managed according to NHLBI 
guidelines and repeat echocardiogram yearly
• mPAP >25 mm Hg and PCWP <15 mm Hg: precapillary pulmonary hypertension
- Perform ventilation/perfusion scan of the lung and consider long-term anticoagulation if segmental defect 
found
- Refer for overnight polysomnography to evaluate for sleep disordered breathing include obstructive sleep 
apnea; provide appropriate intervention if present
- Chronic low-flow oxygen by nasal cannula if pulse ox <90%
- Refer to pulmonary hypertension expert for follow-up and consideration whether endothelin receptor blocker 
or prostacyclin agent should be attempted
- Consider initiating therapy with hydroxyurea if patient is not receiving this medication or with exchange blood 
transfusion program if patient does not tolerate or respond to hydroxyurea
- Consider allogenic hematopoietic stem cell transplantation with low intensity conditioning regimen if patient 
has HLA matched sibling.
• mPAP >25 mm Hg and PCWP >15 mm Hg: postcapillary pulmonary hypertension
- Refer to cardiologist to evaluate for left ventricular systolic or diastolic dysfunction; manage according to 
established guidelines for left ventricular failure
- Consider initiating therapy with hydroxyurea if patient not receiving this medication or with exchange blood 
transfusion program if patient does not tolerate or respond to hydroxyurea
- Consider allogenic hematopoietic stem cell transplantation with low intensity conditioning regimen if patient 
has HLA matched sibling
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[82]Adapted from Gordeuk et al. Blood 2016; 127(7): 820–828
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